Alector Q2 net loss $30.5M; cash $307.3M; Phase 3 latozinemab data mid-Q4

Alector, Inc.

2025-Q2 EPS reported -$0.71 revenue$11,548,000

Net loss $30.5M ($0.30/sh) vs $38.7M ($0.40/sh) in Q2 2024; revenue $7.9M down from $15.1M.
Cash, cash equivalents, and investments $307.3M, providing runway into H2 2027.
On track to report topline data from INFRONT-3 Phase 3 trial of latozinemab in FTD-GRN by mid-Q4 2025.
Guidance updated: collaboration revenue $13-18M, R&D expenses $130-140M, G&A $55-65M for FY2025.
Neil Berkley appointed interim CFO; USPTO issued patent for latozinemab treatment method.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.